Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087.

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH.

Blood. 2019 Aug 13. pii: blood.2019000324. doi: 10.1182/blood.2019000324. [Epub ahead of print]

PMID:
31409671
2.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492. [Epub ahead of print]

PMID:
31398081
3.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G.

J Clin Oncol. 2019 Jul 24:JCO1901073. doi: 10.1200/JCO.19.01073. [Epub ahead of print]

PMID:
31339826
4.

Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma.

Dobos G, Battistella M, Jouenne F, Mourah S, Vignon-Pennamen MD, Ram-Wolff C, Herms F, Dauendorffer JN, Rivet J, Cayuela JM, Bouaziz JD, Brice P, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jul 6. doi: 10.1111/bjd.18328. [Epub ahead of print]

PMID:
31278742
5.

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.

Dumont M, Ram-Wolff C, Roelens M, Brice P, de Latour RP, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz JD, Moins-Teisserenc H, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18215. [Epub ahead of print]

PMID:
31206589
6.

Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation.

Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Brice P, Morice P, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Gouy S, Chalas C, Egels S, Dhédin N, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N; CAROLéLISA Cooperative Group.

Hum Reprod. 2019 Jun 4;34(6):1083-1094. doi: 10.1093/humrep/dez047.

PMID:
31116405
7.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R; LYSA.

Eur J Cancer. 2019 Jul;115:47-56. doi: 10.1016/j.ejca.2019.04.006. Epub 2019 May 10.

PMID:
31082693
8.

Romidepsin is an effective and well-tolerated therapy in CD3-CD4+ lymphocyte-variant hypereosinophilic syndrome: A case report.

Baulier G, Asli B, Galicier L, Fieschi C, Brice P, Malphettes M.

J Allergy Clin Immunol Pract. 2019 May 10. pii: S2213-2198(19)30443-X. doi: 10.1016/j.jaip.2019.04.039. [Epub ahead of print] No abstract available.

PMID:
31078759
9.

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.

Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS.

Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112. [Epub ahead of print] No abstract available.

PMID:
31014144
10.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.

von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Zinzani PL, Giezek H, Balakumaran A, Vo TT, Raut M, Brice P.

Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262. [Epub ahead of print]

PMID:
31012356
11.

PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Berriolo-Riedinger A, Fornecker LM, André M, Meignan M.

Lancet Oncol. 2019 Apr;20(4):e190. doi: 10.1016/S1470-2045(19)30156-1. No abstract available.

PMID:
30942177
12.

Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies.

Dercle L, Mokrane FZ, Schiano de Colella JM, Stamatoullas A, Morschhauser F, Brice P, Ghesquières H, Casasnovas O, Chen A, Manson G, Houot R.

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1391-1392. doi: 10.1007/s00259-019-04310-x. Epub 2019 Mar 19. No abstract available.

PMID:
30888476
13.

Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies.

Poirot C, Fortin A, Dhédin N, Brice P, Socié G, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Chalas C, Egels S, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N.

Haematologica. 2019 Aug;104(8):e360-e363. doi: 10.3324/haematol.2018.211094. Epub 2019 Feb 14. No abstract available.

14.

Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.

Quéro L, Gilardin L, Fumagalli I, Martin V, Guillerm S, Bauduceau O, Kirova YM, Hennequin C, Brice P.

Cancer Radiother. 2019 Apr;23(2):132-137. doi: 10.1016/j.canrad.2018.05.002. Epub 2019 Feb 4.

PMID:
30733172
15.

Alopecic patches of the scalp: a variant of primary cutaneous follicle centre B-cell lymphoma reported in a series of 14 cases.

de Masson A, Bouaziz JD, Ram-Wolff C, Brice P, Moulonguet I, Vignon-Pennamen MD, Herms F, Verneuil L, Rivet J, Bagot M, Battistella M.

J Eur Acad Dermatol Venereol. 2019 May;33(5):e209-e211. doi: 10.1111/jdv.15477. Epub 2019 Mar 1. No abstract available.

PMID:
30716178
16.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
17.

L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.

Gilardin L, Amorim S, Bernard S, Ravdan O, Thieblemont C, Brice P.

Bull Cancer. 2018 Dec;105 Suppl 1:S50-S58. doi: 10.1016/S0007-4551(18)30390-4. Review. French.

PMID:
30595199
18.

Thymic localization of erythrodermic cutaneous T-cell lymphoma.

Bonnet P, Battistella M, Bouaziz JD, Ram-Wolff C, Frumholtz L, Herms F, Clerc G, Bonhomme A, Brice P, Bagot M, de Masson A.

Br J Dermatol. 2019 Feb;180(2):427-428. doi: 10.1111/bjd.17340. Epub 2018 Dec 13. No abstract available.

PMID:
30339741
19.

Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.

Bonnet P, Battistella M, Roelens M, Ram-Wolff C, Herms F, Frumholtz L, Bouaziz JD, Brice P, Moins-Teisserenc H, Bagot M, de Masson A.

Br J Dermatol. 2019 Feb;180(2):419-420. doi: 10.1111/bjd.17320. Epub 2018 Nov 22. No abstract available.

PMID:
30328116
20.

Dramatic response to brentuximab vedotin in refractory nontransformed CD30- mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission.

Mahévas T, Ram-Wolff C, Battistella M, Pennamen MDV, Rivet J, Brice P, Bagot M.

Br J Dermatol. 2019 Jun;180(6):1517-1520. doi: 10.1111/bjd.17254. Epub 2019 Jan 1.

PMID:
30269331
21.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.

N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.

22.

Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA).

Br J Haematol. 2018 Oct;183(1):76-86. doi: 10.1111/bjh.15513. Epub 2018 Aug 16.

PMID:
30117149
23.

Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?

Barp A, Gilardin L, Afanasiev V, Delorme C, Viala K, Bernard S, Brice P, Psimaras D, Lenglet T.

Leuk Lymphoma. 2019 Feb;60(2):547-549. doi: 10.1080/10428194.2018.1485912. Epub 2018 Jul 22. No abstract available.

PMID:
30033838
24.

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H.

Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. [Epub ahead of print]

25.

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.

Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, Ghesquieres H, Dercle L, Houot R; Lymphoma Study Association.

Blood. 2018 Jun 21;131(25):2856-2859. doi: 10.1182/blood-2018-03-841262. Epub 2018 May 3. No abstract available.

26.

Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.

Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, Marolleau JP, Oberic L, Le Du K, Fornecker LM, Tournilhac O, Veillard AS, Chaillol I, Robin M, Tamburini J, Brice P.

Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184. Epub 2018 Apr 2.

PMID:
29611187
27.

Refractory Hodgkin lymphoma: time for targeted therapies?

Brice P.

Blood. 2018 Mar 15;131(11):1156-1157. doi: 10.1182/blood-2017-12-824136. No abstract available.

28.

Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.

Feugier P, Brice P, Maynadié M, Franchi-Rezgui P, Hacini M, Laurent G, Suc E, Fitoussi O, Solal-Celigny P, Damaj G, Haioun C, Leconte P, Lazreg F, Boissard F, Pau D, Salles G.

Leuk Lymphoma. 2018 Oct;59(10):2485-2488. doi: 10.1080/10428194.2018.1434878. Epub 2018 Feb 28. No abstract available.

PMID:
29486625
29.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G.

Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20. Erratum in: Lancet Oncol. 2018 Jun;19(6):e283.

30.

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.

Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Van Zele E, Chartier L, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M, Meignan M.

Blood. 2018 Mar 29;131(13):1456-1463. doi: 10.1182/blood-2017-07-795476. Epub 2018 Feb 1.

31.

Positive Psychology in Research with the Deaf Community: An Idea Whose Time Has Come.

Szarkowski A, Brice P.

J Deaf Stud Deaf Educ. 2018 Apr 1;23(2):111-117. doi: 10.1093/deafed/enx058. Review.

PMID:
29432607
32.

Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.

Rossi C, Mounier M, Brice P, Safar V, Nicolas-Virelizier E, Rey P, Stamatoullas-Bastard A, Alcantara M, Chauchet A, Reboursière E, Filliatre L, Perrot A, Garciaz S, Salles G, Coiffier B, Ghesquières H, Casasnovas RO.

Oncotarget. 2017 Jul 19;8(49):85110-85119. doi: 10.18632/oncotarget.19389. eCollection 2017 Oct 17.

33.

Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients.

Bigenwald C, Galimard JE, Quero L, Cabannes-Hamy A, Thieblemont C, Boissel N, Brice P.

Oncotarget. 2017 Sep 6;8(45):80073-80082. doi: 10.18632/oncotarget.20684. eCollection 2017 Oct 3.

34.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A.

Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3. Erratum in: Blood. 2018 Jul 26;132(4):458-459.

35.

18F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin.

Ram-Wolff C, Vercellino L, Brice P, La Selva R, Bagot M.

Eur J Dermatol. 2017 Oct 1;27(5):496-504. doi: 10.1684/ejd.2017.3083.

PMID:
28721937
36.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte.

Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8.

PMID:
28601705
37.

Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients.

Ingen-Housz-Oro S, Pham-Ledard A, Brice P, Lebrun-Vignes B, Zehou O, Reitter D, Ram-Wolff C, Dupin N, Bagot M, Chosidow O, Beylot-Barry M.

Eur J Dermatol. 2017 Jun 1;27(3):271-274. doi: 10.1684/ejd.2017.2986.

PMID:
28524061
38.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087.

J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.

39.

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G; a LYSA study.

Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13.

PMID:
28414090
40.

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J.

J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.

PMID:
28291393
41.

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F.

Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7.

42.

Fertility preservation before an ABVD protocol: no new evidence to support changing the recommendations.

Poirot C, Dhedin N, Brice P.

Future Oncol. 2017 Mar;13(7):589-590. doi: 10.2217/fon-2016-0441. Epub 2016 Dec 6. No abstract available.

43.

Reply to M. Lambertini et al.

Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y.

J Clin Oncol. 2017 Mar;35(7):805-806. doi: 10.1200/JCO.2016.70.6093. Epub 2016 Nov 28. No abstract available.

PMID:
27893330
44.

[Hodgkin and non-Hodgkin lymphoma of adolescents and young adults].

Garciaz S, Coso D, Brice P, Bouabdallah R.

Bull Cancer. 2016 Dec;103(12):1035-1049. doi: 10.1016/j.bulcan.2016.10.011. Epub 2016 Nov 17. Review. French.

PMID:
27866679
45.

Organizational profile: PHG Foundation.

Brice P.

Per Med. 2016 Nov;13(6):513-516. doi: 10.2217/pme-2016-0069. Epub 2016 Oct 13.

PMID:
29754543
46.

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P.

Br J Haematol. 2018 Jan;180(2):304-308. doi: 10.1111/bjh.14323. Epub 2016 Sep 23. No abstract available.

PMID:
27662562
47.

Lymphoma in Adolescents and Young Adults.

Brugières L, Brice P.

Prog Tumor Res. 2016;43:101-14. doi: 10.1159/000447080. Epub 2016 Sep 5. Review.

PMID:
27595360
48.

Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma.

Krebs L, Amorin S, Brice P, Guillerm S, Menard J, Hennequin C, Quéro L.

Strahlenther Onkol. 2017 Feb;193(2):116-124. doi: 10.1007/s00066-016-0969-9. Epub 2016 Jun 17.

PMID:
27316376
49.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H.

J Clin Oncol. 2016 Aug 1;34(22):2575-82. doi: 10.1200/JCO.2015.65.7163. Epub 2016 Jun 13. Erratum in: J Clin Oncol. 2016 Sep 10;34(26):3230.

PMID:
27298402
50.

No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.

Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y.

J Clin Oncol. 2016 Aug 1;34(22):2568-74. doi: 10.1200/JCO.2015.65.8864. Epub 2016 May 23.

PMID:
27217453

Supplemental Content

Support Center